Skip to Main Content
Phase II

KD025-215 and diffuse cutaneous systemic sclerosis

  • Study HIC#:2000029154
  • Last Updated:08/16/2021

The purpose of this study is to test whether a drug called belumosudil (KD025) is a good treatment for patients with diffuse cutaneous systemic sclerosis (dcSSc). This open-label trial will last approximately 14 months, with visits typically occurring once a month.

  • Age18 years and older
  • GenderBoth
  • Start Date02/08/2021
  • End Date12/31/2021

Trial Purpose and Description

The purpose of this study is to test whether a drug called belumosudil (KD025) is a good treatment for patients with diffuse cutaneous systemic sclerosis (dcSSc). This open-label trial will last approximately 14 months, with visits typically occurring once a month.

Eligibility Criteria

Inclusion:

  • Age 18+
  • Diagnosed with diffuse cutaneous systemic sclerosis (dcSSc) according to 2013 ACR/ EULAR criteria
  • Scleroderma disease duration of less than or up to 6 years
  • Active skin diseaseĀ 

Exclusion:

  • Pregnant or breastfeeding
  • Chronic heart failure
  • Diagnosed with any malignancy within 3 years of enrollmentĀ 
  • Scleroderma renal crisis within 4 months of enrollment
  • Severe lung disease

For more information about this study, contact:

Or contact the Help us Discover team on: